MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research Abstracts at the NASH-TAG Annual Conference

04 Jan 2024 08:00:01 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 16:30:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

22 Dec 2023 16:30:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

27 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Ronald Filippo as Chief Information Officer

21 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

15 Nov 2023 16:45:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents New Data from the Phase 3 MAESTRO-NASH Trial Demonstrating Broad Treatment Effects of Resmetirom on Noninvasive Measures of Liver Health

10 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Carole Huntsman as Chief Commercial Officer

10 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Third Quarter 2023 Financial Results

06 Nov 2023 08:00:01 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

02 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

12 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

28 Sep 2023 22:30:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Proposed Public Offering

28 Sep 2023 16:01:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

14 Sep 2023 16:30:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

13 Sep 2023 09:10:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

11 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Second Quarter 2023 Financial Results

08 Aug 2023 08:00:01 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Completes Submission of New Drug Application Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

17 Jul 2023 08:00:01 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Rolling Submission of New Drug Application to U.S. FDA Seeking Accelerated Approval of Resmetirom for the Treatment of NASH with Liver Fibrosis

30 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Presents Phase 3 MAESTRO-NASH Data During the Opening General Session of the EASL Congress™

22 Jun 2023 03:30:00 By Nasdaq GlobeNewswire